Bioxcel Therapeutics Share Price Today: Live Updates & Key Insights

Bioxcel Therapeutics share price today is $1.5394, up -5.63%. The stock opened at $1.605 against the previous close of $1.6, with an intraday high of $1.61 and low of $1.495.

Bioxcel Therapeutics Share Price Chart

Bioxcel Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Bioxcel Therapeutics Share Price Performance

$1.5394 -0.0563(-5.63%) BTAI at 23 Mar 2026 12:19 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.495
Highest Today 1.61
Today’s Open 1.605
Prev. Close 1.6
52 Week High 8.08
52 Week Low 1.17
Day’s Range: Low 1.495 High 1.61
52-Week Range: Low 1.17 High 8.08
1 day return -
1 Week return -1.62
1 month return -6.79
3 month return -14.2
6 month return -45.87
1 year return -33.48
3 year return -91.53
5 year return -96.73
10 year return -

Bioxcel Therapeutics Institutional Holdings

Millennium Management LLC 8.39

Vanguard Group Inc 1.34

Oaktree Capital Management LLC 1.10

Vanguard Institutional Extnd Mkt Idx Tr 0.95

Geode Capital Management, LLC 0.94

Jane Street Group LLC 0.58

GSA Capital Partners LLP 0.55

XTX Topco Ltd 0.52

Fidelity Extended Market Index 0.48

Abante Quant Value FI 0.44

Fidelity Select Biotechnology 0.41

FMR Inc 0.41

BlackRock Inc 0.39

Blackrock Extended Mkt Fund CF 0.32

Extended Equity Market Fund K 0.27

Man Group PLC 0.26

State Street Corp 0.24

UBS Group AG 0.20

Oaktree Fund Advisors, LLC 0.20

HighTower Advisors, LLC 0.19

Northern Trust Corp 0.17

JONES FINANCIAL COMPANIES LLLP 0.16

Fidelity Total Market Index 0.16

Fidelity Series Total Market Index 0.12

Spartan Extended Market Index Pool F 0.11

NT Ext Equity Mkt Idx Fd - NL 0.10

HRT FINANCIAL LLC 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.08

TWO SIGMA SECURITIES, LLC 0.08

Wells Fargo & Co 0.07

Advisor Group Holdings, Inc. 0.07

Spartan Total Market Index Pool G 0.07

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

Extended Equity Market Fund M 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Oaktree Diversified Income Fund Inc D 0.02

NT US Market Cap Idx Fd - L 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

Bioxcel Therapeutics Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 1

Strong Sell: 0

Bioxcel Therapeutics Fundamentals

Market Cap 36.77 M

PB Ratio 3.9656

PE Ratio 0.0

Enterprise Value 109.88 M

Total Assets 38.34 M

Volume 695880

Bioxcel Therapeutics Company Financials

Annual Revenue FY23:1242000 1.2M, FY22:375000 0.4M, FY21:0 0.0M, FY20:24 0.0M, FY19:0 0.0M

Annual Profit FY23:687000 0.7M, FY22:355000 0.4M, FY21:null 0.0M, FY20:24 0.0M, FY19:null 0.0M

Annual Net worth FY23:-211605000 -211.6M, FY22:-171849000 -171.8M, FY21:-106630000 -106.6M, FY20:-82008000 -82.0M, FY19:-32335000 -32.3M

Quarterly Revenue Q3/2025:98000 0.1M, Q2/2025:120000 0.1M, Q1/2025:168000 0.2M, Q3/2024:214000 0.2M, Q2/2024:1104000 1.1M

Quarterly Profit Q3/2025:12000 0.0M, Q2/2025:13000 0.0M, Q1/2025:154000 0.2M, Q3/2024:-956000 -1.0M, Q2/2024:1042000 1.0M

Quarterly Net worth Q3/2025:-30911000 -30.9M, Q2/2025:-19187000 -19.2M, Q1/2025:-7254000 -7.3M, Q3/2024:-13650000 -13.7M, Q2/2024:-8298999 -8.3M

About Bioxcel Therapeutics & investment objective

Company Information BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Organisation Drug Manufacturers - Specialty & Generic

Employees 37

Industry Drug Manufacturers - Specialty & Generic

CEO Dr. Vimal D. Mehta Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Bioxcel Therapeutics FAQs

What is the share price of Bioxcel Therapeutics today?

The current share price of Bioxcel Therapeutics is $1.5394.

Can I buy Bioxcel Therapeutics shares in India?

Yes, Indian investors can buy Bioxcel Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Bioxcel Therapeutics shares in India?

You can easily invest in Bioxcel Therapeutics shares from India by:

Can I buy fractional shares of Bioxcel Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Bioxcel Therapeutics?

Bioxcel Therapeutics has a market cap of $36.77 M.

In which sector does Bioxcel Therapeutics belong?

Bioxcel Therapeutics operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Bioxcel Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Bioxcel Therapeutics?

The PE ratio of Bioxcel Therapeutics is N/A and the PB ratio is 3.97.